Barrow Robert's Form 4/A amendment
AmendedDefinium Therapeutics, Inc. (DFTX) · filed May 19, 2022
- Accession no.
- 0001209191-22-030499
- Filed
- May 19, 2022
- Trade date
- May 18, 2022
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
- Original filed
- May 17, 2022
This filing lists 1 non-derivative transaction. Open-market sales total $13.5K. It was filed 1 day after the trade.
This amendment replaces 0001209191-22-029901 (filed May 17, 2022).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Barrow RobertCIK 0001897557 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 18, 2022 | Subordinate Voting Shares | SSaleDisposed | −18,948 | $0.71F2 | −$13,453.08 | 3,995,309 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Subordinate Voting Shares sold to satisfy withholding tax obligations upon the delivery of Subordinate Voting Shares for restricted stock units that vested on May 15, 2022.
- F2
The Subordinate Voting Shares were sold in one transaction at a price of $0.92 CAD Dollars. This represents the price in United States Dollars using the conversion rate on May 18, 2022.
Referenced by the price of 1 transaction in Table I.
Remarks
Explanatory Note: This Amendment on Form 4/A is being filed to amend the Form 4 filed on May 17, 2022 solely to update the following information in Table 1: the Transaction Date, the Transaction Code, the Price and Explanation of Responses 1 and 2.